NOVARTIS for NOVARTIS
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Animals ANI
Animal Drug User Fee Re-authorization (ADUFA) HR 1150 - Preservation of Antibiotics for Medical Treatment Act of 2013 Oppose legislation detrimental to strong vet/pet/client relationship Drug compounding (animal)
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENDA J LUCKRITZ | — |
Taxation/Internal Revenue Code TAX
Orphan Drug Tax Credit
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| DAVID DRAKE | — |
| SARAH HALLER | — |
| BRENDA J LUCKRITZ | — |
| SHAWN O'NEAIL | — |
| KATHERINE SOLON | — |
Medicare/Medicaid MMM
Access to Life Saving Medicines Act Provide Medicare Part B Coverage for Vaccines Covered under Part D Medicaid Coverage of Vaccines
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| DAVID DRAKE | — |
| SARAH HALLER | — |
| BRENDA J LUCKRITZ | — |
| SHAWN O'NEAIL | — |
| KATHERINE SOLON | — |
Trade (domestic/foreign) TRD
Free Trade Agreements: - Intellectual Property Provisions - Free Trade Agreements Access to Medicines Global Health IssuesIndia IP Trans-Pacific Partnership FTA Sub-standards Medicines Quality of Medicines
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH HALLER | — |
| SHAWN O'NEAIL | — |
Budget/Appropriations BUD
Pandemic Influenza Funding FDA Appropriations funding for Generic Drugs Certified Importer Program (CIP) FY 2013 - Labor HHS Appropriations Bill
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| DAVID DRAKE | — |
| SARAH HALLER | — |
| BRENDA J LUCKRITZ | — |
| SHAWN O'NEAIL | — |
| KATHERINE SOLON | — |
Health Issues HCR
Gene Therapy Personalized Medicine Section 9008 of Patient Protection and Affordable Care Act Dextromethorphan - Age Restrictions - Controlling bulk shipments - PACT ActPseudoephedrine - Promote e-tracking; oppose Rx legislation FSA/HSA - Support reinstating coverage of OTC products Enhance supply and shipping parameters for beta-Propiolactone HR 351/S 351 - Medicine Decisions Act of 2011 (IPAB) 340B Drug Discount Program Dual Eligibles Program Drug Distribution Security (Track & Trace) Certified Importer Program MDUFA (Medical Device User Fee Act) Implementation Medical Device Tax Repeal Drug Importation Limitations on lawful use of caffeine Reimbursement for medical devices
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| DAVID DRAKE | — |
| SARAH HALLER | — |
| BRENDA J LUCKRITZ | — |
| SHAWN O'NEAIL | — |
| KATHERINE SOLON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.